Liberty Global Ltd Class C vs Repligen Corporation Common Stock — how do they compare? Liberty Global Ltd Class C trades at $8.03 (market cap $2.94B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.8× Liberty Global Ltd Class C's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 20 Days and Repligen Corporation Common Stock for 0 Days on average.
| LBTYK | RGEN | |
|---|---|---|
Market Cap | $2.94B | $11.14B |
Volume | 1,441,876 | 1,259,263 |
Sector | Media | Health |
52-Week High | $12.67 | $194.57 |
52-Week Low | $8.03 | $102.87 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $9.60B | $11.02B |
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.41, showing minimal daily movement with a 0.24% gain. The stock faces bearish technical signals but maintains strong analyst support with 69% buy ratings and a $12.67 consensus target. Recent financials show mixed performance with negative net income margins (-62.14%) despite solid gross margins (67.17%), while strategic moves like the Ziggo Group spin-off and AI partnerships aim to unlock value by 2027.
The outlook remains cautiously optimistic given the significant upside to analyst targets and ongoing corporate restructuring. Key risks include persistent profitability challenges and execution risks around the Ziggo listing. The stock's deep value proposition (P/S 0.59, P/B 0.31) offers potential for patient investors despite near-term volatility.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →